First Patient Dosed in Phase II Basket Trial of Taletrectinib for Solid Tumors with NTRK Fusion
June 17, 2021 20:00 ET
|
AnHeart Therapeutics
HANGZHOU, China and SUZHOU, China and NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- AnHeart Therapeutics Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in...
AnHeart and Innovent Releases Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting
June 06, 2021 20:00 ET
|
AnHeart Therapeutics
HANGZHOU, China, June 06, 2021 (GLOBE NEWSWIRE) -- AnHeart Therapeutics Co., Ltd (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets, together with...
AnHeart Therapeutics and Innovent Biologics Announce Exclusive License Agreement for Taletrectinib in Greater China
May 31, 2021 20:00 ET
|
AnHeart Therapeutics
HANGZHOU, China and SUZHOU, China and NEW YORK, May 31, 2021 (GLOBE NEWSWIRE) -- AnHeart Therapeutics Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in...
AnHeart Announces Upcoming Presentation of Preliminary Results from Phase II Trial of Taletrectinib in ROS1+ NSCLC at the ASCO 2021 Virtual Meeting
May 19, 2021 20:00 ET
|
AnHeart Therapeutics
HANGZHOU, China and NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) -- AnHeart Therapeutics Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets,...
AnHeart Announces Publication of Pooled Analysis of two Phase 1 Studies of Taletrectinib in ROS1+ NSCLC
October 29, 2020 08:00 ET
|
AnHeart Therapeutics
HANGZHOU, China and NEW YORK, Oct. 29, 2020 (GLOBE NEWSWIRE) -- AnHeart Therapeutics, Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets,...
AnHeart Licenses Two Clinical Stage Oncology Candidates from Daiichi Sankyo
September 07, 2020 20:00 ET
|
AnHeart Therapeutics
Expanding Oncology Pipeline to Three Novel Molecules Following its Series A+ Financing Round HANGZHOU, China and NEW YORK, Sept. 07, 2020 (GLOBE NEWSWIRE) -- AnHeart Therapeutics, Co., Ltd....
AnHeart Announces Entry into Series A+ Equity Financing Agreements
August 09, 2020 20:00 ET
|
AnHeart Therapeutics
HANGZHOU, China and NEW YORK, Aug. 09, 2020 (GLOBE NEWSWIRE) -- AnHeart Therapeutics, Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets, has...
AnHeart to Present Corporate Update at LifeSci Partners Summer Symposium
July 24, 2020 07:00 ET
|
AnHeart Therapeutics
SHANGHAI, China and NEW YORK, July 24, 2020 (GLOBE NEWSWIRE) -- AnHeart Therapeutics, Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets,...
First Patient Dosed with Taletrectinib in AnHeart Phase 2 Trial of Non-Small Cell Lung Cancer with ROS1 Fusion
July 21, 2020 08:00 ET
|
AnHeart Therapeutics
SHANGHAI, China and NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) -- AnHeart Therapeutics, Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets,...
AnHeart Therapeutics Announces License Agreement with NewG Lab for Taletrectinib Rights in Korea
July 15, 2020 08:00 ET
|
AnHeart Therapeutics
HANGZHOU, China and NEW YORK, July 15, 2020 (GLOBE NEWSWIRE) -- AnHeart Therapeutics, Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets,...